Bristol-Myers Squibb and Oncolys BioPharma Enter Global Licensing Agreement

Bristol-Myers SquibbBristol-Myers Squibb Company (NYSE:BMY) and Oncolys BioPharma Inc., a privately held biotechnology company based in Japan, have signed a definitive agreement under which Bristol-Myers Squibb will acquire exclusive worldwide rights to manufacture, develop and commercialize festinavir, a once-a-day, orally available nucleoside reverse transcriptase inhibitor (NRTI) in Phase II development for HIV.

Under the terms of the agreement, Oncolys may receive up to $286 million including upfront, development, regulatory and sales milestone payments. Oncolys is also eligible to receive tiered royalties on the worldwide product sales.

"Bristol-Myers Squibb has been dedicated to helping patients prevail over HIV for more than two decades and is committed to the ongoing discovery, development and delivery of medicines to fight HIV/AIDS globally," said Brian Daniels, senior vice president, Development. "The profile of festinavir offers the possibility of improvement in the safety of long-term HIV treatment, an area of significant unmet medical need."

President & CEO of Oncolys BioPharma, Mr. Yasuo Urata said, "I'm honored to have completed this license agreement with Bristol-Myers Squibb for the development and commercialization of festinavir. For many years I have been working for the development of medicines in the fight against HIV/AIDS, and I'm convinced that festinavir has the possibility to be a potent and effective NRTI with a promising resistance profile. Also festinavir's once-daily dosage is essential for treating HIV patients worldwide."

About Festinavir
Festinavir is a next-generation, orally available nucleoside reverse transcriptase inhibitor (NRTI) in Phase II development for HIV. Early preclinical studies suggest that festinavir could have an improved safety profile over previous generations of NRTIs. Festinavir was licensed to Oncolys in 2006 from Yale University.

About Bristol-Myers Squibb
Bristol-Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases.

About Oncolys BioPharma
Oncolys BioPharma is a clinical-stage Japanese biotechnology company whose mission is to serve patients, and develop effective, innovative, and safe drugs through novel approaches with the goal of treating people worldwide from cancer and serious infectious diseases. Oncolys BioPharma focuses on the development and partnering of not only HIV drug but also anti-hepatitis C and anti-cancer drugs.

Most Popular Now

AstraZeneca COVID-19 vaccine Vaxzevria authorised …

AstraZeneca's COVID-19 vaccine, Vaxzevria (ChAdOx1-S [Recombinant]), formerly AZD1222, has been granted a special approval for emergency use in Japan for active immunisat...

Pfizer and BioNTech to supply the European Union w…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced a new agreement with the European Commission (EC) to supply 900 million doses of COMIRNATY®, the companie...

Takeda announces approval of Moderna's COVID-19 va…

Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) ("Takeda") today announced that the Ministry of Health, Labour and Welfare (MHLW) granted special approval under...

Sanofi and GSK initiate global Phase 3 clinical ef…

Today, Sanofi and GlaxoSmithKline plc (GSK) started enrolment in their Phase 3 clinical study to assess the safety, efficacy and immunogenicity of their adjuvanted recomb...

Sanofi and GSK COVID-19 vaccine candidate demonstr…

The Sanofi and GSK adjuvanted recombinant COVID-19 vaccine candidate achieved strong rates of neutralizing antibody responses, in line with those measured in people who h...

European Commission approves Venclyxto-based combi…

Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the European Commission has approved Venclyxto® (venetoclax) in combination with hypomethylating agents, azacitidi...

Novartis reaches milestone delivery of 1 billion c…

Novartis announced that it has delivered one billion courses of antimalarial treatment since 1999. More than 90% of this artemisinin-based combination therapy (ACT) was s...

COVID-19 mRNA vaccines are immunogenic in pregnant…

Pregnant women with symptomatic COVID-19 have a higher risk of intensive care unit admissions, mechanical ventilation and death compared to non-pregnant reproductive age ...

Why are some COVID-19 vaccines working better for …

MSU researcher is studying, raising awareness about the role of sex in the efficacy of vaccines that make use of nanomedicine. If there's one take-home message for the...

Rogue antibodies wreak havoc in severe COVID-19 ca…

The development of antibodies to the COVID-19 virus has been the great long-term hope of ending the pandemic. However, immune system turncoats are also major culprits in ...

New vaccine platform: 'Two-one replicon-and-VLP-mi…

To stop the current SARS-CoV-2 pandemic, vaccines of high quality, safety, and efficacy are required. Scientists of the Paul-Ehrlich-Institut and the Ludwig Maximilian Un...

COVID-19 monoclonal antibodies reduce risk of hosp…

Monoclonal antibodies, a COVID-19 treatment given early after coronavirus infection, cut the risk of hospitalization and death by 60% in those most likely to suffer compl...